Traders Are Watching Closely Illumina, Edwards Lifesciences & Three Other Stocks Today

Edwards Soars on Results

Edwards Lifesciences Corp (NYSE:EW) bulls are having a good day after the company reported EPS of $0.76 on sales of $759.3 million for the second quarter, beating the consensus estimates by $0.06 per share and $35.04 million, respectively. Shares of the company are higher as sales rose by 22.1% year-over-year and full 2016 revenue is seen coming in at the high end of the previously communicated range of $2.7 billion to $3 billion. 2016 adjusted EPS estimate has also been increased to the range of $2.78 to $2.88 as demand for the company’s products remains strong. Among the funds we follow, 45 funds were long Edwards Lifesciences Corp (NYSE:EW) at the end of the first quarter, up by eight funds from the previous quarter.

Follow Edwards Lifesciences Corp (NYSE:EW)

Quintiles Retreats Despite Solid Quarter

Although its earnings beat estimates by $0.03 per share and its sales exceeded the consensus by $20 million, traders were evidently expecting more from Quintiles Transnational Holdings Inc (NYSE:Q)‘s second quarter. Shares of the company are down 3.5% in afternoon trading despite the company reporting EPS of $0.93 on sales of $1.17 billion (up by 9.3% year-over-year). The book-to-bill ratio was 1.41 for the time period while the backlog amounted to $12.5 billion as of June 30, 2016. Full-year adjusted EPS guidance is $3.78 to $3.88, representing an annual growth of 13.5% to 16.5%. Cliff Asness’ AQR Capital Management owned more than 2.1 million shares of Quintiles Transnational Holdings Inc (NYSE:Q) at the end of the first quarter.

Follow Iqvia Holdings Inc.

Wyndham in the Red

Traders are watching Wyndham Worldwide Corporation (NYSE:WYN) today after the company delivered earnings of $1.40 per share on sales of $1.4 billion in the second quarter. Although Wyndham’s profit beat the consensus estimate by $0.03 per share, its sales missed the expectations by $40 million and the company’s Domestic REVPAR rose by only 2.4% year-over-year. For full 2016, management estimates adjusted diluted EPS in the range of $5.68 to $5.82, based on a diluted share count of 112 million. Adjusted EBITDA is seen coming in at $1.375 billion to $1.4 billion and revenue is seen to be in the range of $5.65 billion to $5.8 billion. At the end of the first quarter, 23 funds owned $1.07 billion worth of Wyndham Worldwide Corporation (NYSE:WYN)’s stock, which accounted for 12.50% of the float, versus 27 funds and $1.19 billion, respectively, a quarter earlier.

Follow Wyndham Destinations Inc. (NYSE:WYND)

Disclosure: none